Chemotherapy
Riluzole + Sorafenib for Melanoma
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial tests the safety and best dose of combining riluzole and sorafenib tosylate for patients with advanced solid tumors or melanoma that don't respond to standard treatments. Riluzole may slow tumor growth, and sorafenib tosylate blocks processes needed for tumor growth. The combination aims to kill more tumor cells.
Virus Therapy
Talimogene Laherparepvec + Pembrolizumab for Skin Cancer
Recruiting1 awardPhase 2
Mobile, Alabama
This trial is studying how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
CAR T-cell Therapy
Gene-Modified T Cells for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is testing the side effects and best dose of gene-modified T cells, given with or without decitabine, to treat patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced).
Nonsteroidal Anti-inflammatory Drug
Topical Diclofenac for Non-melanoma Skin Cancer
Recruiting0 awardsPhase 2
Birmingham, Alabama
This trial will study the effects of a topical medication, diclofenac, on the prevention of non-melanoma skin cancers. The study will also assess the optimal dose of the medication. Diclofenac is already approved by the FDA for other uses. 24 patients will be enrolled in the study.
Popular Filters
Trials for Squamous Cell Carcinoma Patients
Immunotherapy
OBX-115 for Skin Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a new treatment called OBX-115 for adults with advanced solid tumors. It aims to see if the treatment is safe and effective by measuring its ability to shrink tumors, control disease progression, and improve survival.
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
B-cell lymphoma-2 (BCL-2) inhibitor
Navitoclax + Dabrafenib + Trametinib for Melanoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying the side effects and best dose of a combination of dabrafenib, trametinib, and navitoclax to treat patients with BRAF mutant melanoma or solid tumors.
CAR T-cell Therapy
Genetically Modified T-Cells + Aldesleukin for Melanoma
Recruiting3 awardsPhase 1
Houston, Texas
This trial is testing genetically modified T-cells followed by aldesleukin to treat melanoma. T-cells are a type of white blood cell that help the body fight infections. Genes that may help the T-cells recognize melanoma cells are placed into the T-cells in the laboratory. Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body. Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells.
Trials for Basal Cell Carcinoma Patients
Immunotherapy
OBX-115 for Skin Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a new treatment called OBX-115 for adults with advanced solid tumors. It aims to see if the treatment is safe and effective by measuring its ability to shrink tumors, control disease progression, and improve survival.
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
B-cell lymphoma-2 (BCL-2) inhibitor
Navitoclax + Dabrafenib + Trametinib for Melanoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying the side effects and best dose of a combination of dabrafenib, trametinib, and navitoclax to treat patients with BRAF mutant melanoma or solid tumors.
CAR T-cell Therapy
Genetically Modified T-Cells + Aldesleukin for Melanoma
Recruiting3 awardsPhase 1
Houston, Texas
This trial is testing genetically modified T-cells followed by aldesleukin to treat melanoma. T-cells are a type of white blood cell that help the body fight infections. Genes that may help the T-cells recognize melanoma cells are placed into the T-cells in the laboratory. Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body. Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells.
Cell Transfer Therapy
Cell Therapy + Chemo + TBI for Skin Cancer
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing whether an experimental treatment for metastatic melanoma, which involves cell therapy, is more effective when given with chemotherapy and total body irradiation, or just with chemotherapy.
Trials for Metastatic Patients
Immunotherapy
OBX-115 for Skin Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a new treatment called OBX-115 for adults with advanced solid tumors. It aims to see if the treatment is safe and effective by measuring its ability to shrink tumors, control disease progression, and improve survival.
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
B-cell lymphoma-2 (BCL-2) inhibitor
Navitoclax + Dabrafenib + Trametinib for Melanoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying the side effects and best dose of a combination of dabrafenib, trametinib, and navitoclax to treat patients with BRAF mutant melanoma or solid tumors.
CAR T-cell Therapy
Genetically Modified T-Cells + Aldesleukin for Melanoma
Recruiting3 awardsPhase 1
Houston, Texas
This trial is testing genetically modified T-cells followed by aldesleukin to treat melanoma. T-cells are a type of white blood cell that help the body fight infections. Genes that may help the T-cells recognize melanoma cells are placed into the T-cells in the laboratory. Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body. Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells.
Trials for BRAF Positive Patients
Immunotherapy
OBX-115 for Skin Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a new treatment called OBX-115 for adults with advanced solid tumors. It aims to see if the treatment is safe and effective by measuring its ability to shrink tumors, control disease progression, and improve survival.
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
B-cell lymphoma-2 (BCL-2) inhibitor
Navitoclax + Dabrafenib + Trametinib for Melanoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying the side effects and best dose of a combination of dabrafenib, trametinib, and navitoclax to treat patients with BRAF mutant melanoma or solid tumors.
Monoclonal Antibodies
Drug Combinations for Advanced Melanoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two different combinations of drugs to treat patients with stage III-IV melanoma that has spread or can't be removed by surgery. The first combination is nivolumab with trametinib and dabrafenib. The second combination is encorafenib with binimetinib. The trial will compare how well the two combinations work and what side effects they cause.
Phase 3 Trials
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
Checkpoint Inhibitor
Nivolumab + Ipilimumab + Sargramostim for Advanced Melanoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Behavioural Intervention
Skin Cancer Prevention Strategies for Skin Cancer
Recruiting2 awardsPhase 3
Salt Lake City, Utah
This trial aims to identify intervention approaches that help people avoid sunburn and motivate sun protection, by testing 3 personalized risk components over 1 year with 528 people.
Anti-metabolites
5-Fluorouracil + Calcipotriene Cream for Skin Cancer
Recruiting3 awardsPhase 2 & 3
Boston, Massachusetts
This trial compares a standard cancer-killing cream with a new, potentially more effective cream. It targets patients with less aggressive skin cancers. The new cream might work better by combining two ingredients to kill cancer cells and prevent new ones from forming.
Checkpoint Inhibitor
Cemiplimab + Surgery for Advanced Skin Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial compares the effectiveness of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer
Trials With No Placebo
Immunotherapy
OBX-115 for Skin Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a new treatment called OBX-115 for adults with advanced solid tumors. It aims to see if the treatment is safe and effective by measuring its ability to shrink tumors, control disease progression, and improve survival.
BRAF Inhibitor
Immunotherapy + Targeted Therapy for Melanoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
B-cell lymphoma-2 (BCL-2) inhibitor
Navitoclax + Dabrafenib + Trametinib for Melanoma
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is studying the side effects and best dose of a combination of dabrafenib, trametinib, and navitoclax to treat patients with BRAF mutant melanoma or solid tumors.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.